Analyst: Science Stock Sports Long-Term Support

The stock is trying to reverse its year-to-date slump

Jake Scott

Deputy Editor

Jul 8, 2024 at 9:20 AM

GILD

Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 2% in pre-market trading, after Raymond James upgraded the stock to "outperform" from "market perform." According to the the brokerage, GILD -- one of Schaeffer's top 2024 picks -- has support over the next five years from two key drug candidates that could increase revenue growth.

Overall, analysts are pessimistic towards toward the security, with 14 of 24 covering firms recommending a "hold," and the stock's average 12-month price target stands at $81.93, which is a 22.9% premium to Friday's close. This leaves room for analysts to follow Raymond James' lead.

Gilead Sciences stock has had a lackluster year on the charts, down 17.7% in 2024. At the end of May, the security touched its lowest level since October 2022, but the pullback was saved by the $62 level. Today, GILD is chipping away at its 12.5% year-over-year deficit.

Follow @Schaeffers

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!